Early Developmental Perturbations in a Human Stem Cell Model of MODY5/HNF1B Pancreatic Hypoplasia
Teo, Adrian Kee Keong
Lau, Hwee Hui
Valdez, Ivan Achel
Kulkarni, Rohit N.
MetadataShow full item record
CitationTeo, Adrian Kee Keong, Hwee Hui Lau, Ivan Achel Valdez, Ercument Dirice, Erling Tjora, Helge Raeder, and Rohit N. Kulkarni. 2016. “Early Developmental Perturbations in a Human Stem Cell Model of MODY5/HNF1B Pancreatic Hypoplasia.” Stem Cell Reports 6 (3): 357-367. doi:10.1016/j.stemcr.2016.01.007. http://dx.doi.org/10.1016/j.stemcr.2016.01.007.
AbstractSummary Patients with an HNF1BS148L/+ mutation (MODY5) typically exhibit pancreatic hypoplasia. However, the molecular mechanisms are unknown due to inaccessibility of patient material and because mouse models do not fully recapitulate MODY5. Here, we differentiated MODY5 human-induced pluripotent stem cells (hiPSCs) into pancreatic progenitors, and show that the HNF1BS148L/+ mutation causes a compensatory increase in several pancreatic transcription factors, and surprisingly, a decrease in PAX6 pancreatic gene expression. The lack of suppression of PDX1, PTF1A, GATA4, and GATA6 indicates that MODY5-mediated pancreatic hypoplasia is mechanistically independent. Overexpression studies demonstrate that a compensatory increase in PDX1 gene expression is due to mutant HNF1BS148L/+ but not wild-type HNF1B or HNF1A. Furthermore, HNF1B does not appear to directly regulate PAX6 gene expression necessary for glucose tolerance. Our results demonstrate compensatory mechanisms in the pancreatic transcription factor network due to mutant HNF1BS148L/+ protein. Thus, patients typically develop MODY5 but not neonatal diabetes despite exhibiting pancreatic hypoplasia.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:26318584
- HMS Scholarly Articles